• Opening the door to innovation
  • Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
  • Characterization and screening of IgG binding to the neonatal Fc receptor
  • A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design
  • Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum

24 Apr 2014

 Opening the door to innovation

Janine Schuurman, Yvo F Graus, Aran F Labrijn, Sigrid Ruuls and Paul WHI Parren


25 Apr 2014

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

Antoine Deslandes


7 Apr 2014

Characterization and screening of IgG binding to the neonatal Fc receptor

Tobias Neuber, Katrin Frese, Jan Jaehrling, Sebastian Jäger, Daniela Daubert, Karin Felderer, Mechthild Linnemann, Anne Höhne, Stefan Kaden, Johanna Kölln, Thomas Tiller, Bodo Brocks, Ralf Ostendorp and Stefan Pabst


16 May 2014

A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design

Jasmine P Davda, Michael G Dodds, Megan A Gibbs, Wendy Wisdom and John Gibbs


16 Apr 2014

 Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum

Alexander Colbert, Amber Umble-Romero, Samantha Prokop, Ren Xu, John Gibbs and Susan Pederson

Current Issue

mAbs

July/August 2014

Volume 6, Issue 4

View current issue

About the cover image
Humanized tumor mice (HTM) were generated by the co-transplantation of human hematopoietic stem cells and human breast cancer cells (overexpressing HER2) into neonatal NOD-scid IL2Rγnull (NSG) mice. As reported by Wege et al in this issue of mAbs, the co-transplantation of the human breast cancer cell line SKBR- 3 induced tumor cell effusion and also tumor dissemination in the brain (cover image; stained with anti-HER2). For more information see Wege et al, pp. 968-77.

Recent Articles